Advances in the treatment of lung cancer
Published: 7 Jun 2010
Views: 9142
Prof Rafael Rosell - University of Barcelona
Prof Rafael Rosell, speaking at the 2010 ELCC conference, talks about the importance of the ELCC 2010 conference and outlines the advances in lung cancer treatment that he has presented at this year's conference.
Watch Prof Rosell's presentation at ESMO 33 on the benefits of customising erlotinib therapy for NSCLC.
Watch Prof Rosell's presentation at ESMO 33 on the benefits of customising erlotinib therapy for NSCLC.
- Categories:
- Lung & pleura
- Targeted molecules
Related Videos
Oncogenesis: Lung cancer
Dr Edgardo Santos - Florida Precision Oncology, GenesisCare, Florida, USA
28 Jul 2021
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC a...
Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China
16 Jul 2021
Lineage plasticity in lung cancer- biological and therapeutic implications
Dr Triparna Sen - Memorial Sloan Kettering Cancer Center, New York, USA
16 Jul 2021
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNS...
Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
6 Jul 2021
Latest updates in exon 20 insertions focusing on targeted therapies, novel appro...
Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho
22 Jun 2021
OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
7 May 2021
UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients...
Dr Satoru Miura - Niigata Cancer Center Hospital, Niigata, Japan
4 May 2021
Efficacy and early discontinuation predictors in NSCLC patients receiving nivolu...
Dr Giulia Pasello - University of Padova, Padua, Italy
4 May 2021
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...
Dr Martina Lorenzi - University of Padua, Padua, Italy
16 Apr 2021
